Evotec SE Announces Fourth Quarter and Full-Year 2025 Results and 2026 Outlook

Evotec SE reported its financial results for the fourth quarter and full year of 2025. The company achieved financial performance at the high end of its guidance, with Q4 group revenues of €253.3 million and full-year revenues of €788.4 million. Adjusted group EBITDA for Q4 was €58.0 million and €41.1 million for the full year. The company highlighted robust execution in key partnerships, including clinical progress with Bristol Myers Squibb and Bayer collaborations. Evotec Biologics (JEB) demonstrated a strong position, marked by a landmark transaction with Sandoz and agreements with BARDA and the Gates Foundation. The company has initiated its Horizon operating model transformation, which includes reducing its footprint to 10 sites and establishing Centers of Excellence, expecting to achieve run-rate cost savings of approximately €75 million by the end of 2027. Dr. Ashiq H. Khan has been appointed as Chief Commercial Officer. For 2026, Evotec anticipates group revenues between €700-780 million and adjusted EBITDA of €0-40 million, with 2026 expected to be a transitional year. The company also provided a mid-term framework (2026-2030) projecting revenue growth to over €1 billion and an adjusted EBITDA margin of 20% by 2028.